507 related articles for article (PubMed ID: 31315489)
21. Gut microbiota derived metabolites in cardiovascular health and disease.
Wang Z; Zhao Y
Protein Cell; 2018 May; 9(5):416-431. PubMed ID: 29725935
[TBL] [Abstract][Full Text] [Related]
22. Gut microbiome and cardiovascular disease.
Zhao Y; Wang Z
Curr Opin Cardiol; 2020 May; 35(3):207-218. PubMed ID: 32068612
[TBL] [Abstract][Full Text] [Related]
23. Streamlining drug discovery assays for cardiovascular disease using zebrafish.
Pott A; Rottbauer W; Just S
Expert Opin Drug Discov; 2020 Jan; 15(1):27-37. PubMed ID: 31570020
[No Abstract] [Full Text] [Related]
24. 'The way to a man's heart is through his gut microbiota'--dietary pro- and prebiotics for the management of cardiovascular risk.
Tuohy KM; Fava F; Viola R
Proc Nutr Soc; 2014 May; 73(2):172-85. PubMed ID: 24495527
[TBL] [Abstract][Full Text] [Related]
25. Diet and Gut Microbial Function in Metabolic and Cardiovascular Disease Risk.
Meyer KA; Bennett BJ
Curr Diab Rep; 2016 Oct; 16(10):93. PubMed ID: 27541295
[TBL] [Abstract][Full Text] [Related]
26. [Gut microbiota and immune crosstalk in metabolic disease].
Burcelin R
Biol Aujourdhui; 2017; 211(1):1-18. PubMed ID: 28682223
[TBL] [Abstract][Full Text] [Related]
27. [Microbiome, diabetes and heart: a novel link?].
Kappel BA; Lehrke M
Herz; 2019 May; 44(3):223-230. PubMed ID: 30847506
[TBL] [Abstract][Full Text] [Related]
28. Gut Microbial Associations to Plasma Metabolites Linked to Cardiovascular Phenotypes and Risk.
Kurilshikov A; van den Munckhof ICL; Chen L; Bonder MJ; Schraa K; Rutten JHW; Riksen NP; de Graaf J; Oosting M; Sanna S; Joosten LAB; van der Graaf M; Brand T; Koonen DPY; van Faassen M; ; Slagboom PE; Xavier RJ; Kuipers F; Hofker MH; Wijmenga C; Netea MG; Zhernakova A; Fu J
Circ Res; 2019 Jun; 124(12):1808-1820. PubMed ID: 30971183
[TBL] [Abstract][Full Text] [Related]
29. The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.
Sanduzzi Zamparelli M; Compare D; Coccoli P; Rocco A; Nardone OM; Marrone G; Gasbarrini A; Grieco A; Nardone G; Miele L
Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483246
[TBL] [Abstract][Full Text] [Related]
30. Gut Microbiome and Response to Cardiovascular Drugs.
Tuteja S; Ferguson JF
Circ Genom Precis Med; 2019 Sep; 12(9):421-429. PubMed ID: 31462078
[TBL] [Abstract][Full Text] [Related]
31. The Metabolic Role and Therapeutic Potential of the Microbiome.
Olofsson LE; Bäckhed F
Endocr Rev; 2022 Sep; 43(5):907-926. PubMed ID: 35094076
[TBL] [Abstract][Full Text] [Related]
32. The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease.
Chakaroun RM; Olsson LM; Bäckhed F
Nat Rev Cardiol; 2023 Apr; 20(4):217-235. PubMed ID: 36241728
[TBL] [Abstract][Full Text] [Related]
33. Interaction between gut microbiome and cardiovascular disease.
Peng J; Xiao X; Hu M; Zhang X
Life Sci; 2018 Dec; 214():153-157. PubMed ID: 30385177
[TBL] [Abstract][Full Text] [Related]
34. Microbial modulation of cardiovascular disease.
Brown JM; Hazen SL
Nat Rev Microbiol; 2018 Mar; 16(3):171-181. PubMed ID: 29307889
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiome and its role in cardiovascular diseases.
Ahmadmehrabi S; Tang WHW
Curr Opin Cardiol; 2017 Nov; 32(6):761-766. PubMed ID: 29023288
[TBL] [Abstract][Full Text] [Related]
36. Implication of gut microbiota metabolites in cardiovascular and metabolic diseases.
Brial F; Le Lay A; Dumas ME; Gauguier D
Cell Mol Life Sci; 2018 Nov; 75(21):3977-3990. PubMed ID: 30101405
[TBL] [Abstract][Full Text] [Related]
37. Impact of Gut Microbiota on Obesity, Diabetes, and Cardiovascular Disease Risk.
Miele L; Giorgio V; Alberelli MA; De Candia E; Gasbarrini A; Grieco A
Curr Cardiol Rep; 2015 Dec; 17(12):120. PubMed ID: 26497040
[TBL] [Abstract][Full Text] [Related]
38. Gut Microbiota as a Target in the Pathogenesis of Metabolic Disorders: A New Approach to Novel Therapeutic Agents.
Ejtahed HS; Soroush AR; Angoorani P; Larijani B; Hasani-Ranjbar S
Horm Metab Res; 2016 Jun; 48(6):349-58. PubMed ID: 27203411
[TBL] [Abstract][Full Text] [Related]
39. Interactions Between Therapeutics for Metabolic Disease, Cardiovascular Risk Factors, and Gut Microbiota.
Ding QY; Tian JX; Li M; Lian FM; Zhao LH; Wei XX; Han L; Zheng YJ; Gao ZZ; Yang HY; Fang XY; Tong XL
Front Cell Infect Microbiol; 2020; 10():530160. PubMed ID: 33194785
[TBL] [Abstract][Full Text] [Related]
40. Gut microbiota and probiotic intervention as a promising therapeutic for pregnant women with cardiometabolic disorders: Present and future directions.
de Brito Alves JL; de Oliveira Y; Carvalho NNC; Cavalcante RGS; Pereira Lira MM; Nascimento LCPD; Magnani M; Vidal H; Braga VA; de Souza EL
Pharmacol Res; 2019 Jul; 145():104252. PubMed ID: 31054952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
